NCT06214689 IDH1 and OCT4 in High Grade Astrocytoma
| NCT ID | NCT06214689 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assiut University |
| Condition | High Grade Astrocytoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 35 participants |
| Start Date | 2024-09 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35 participants in total. It began in 2024-09 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
observation of IDH1 and OCT4 markers level and high grade astrocytoma patients prognosis after excision.
Eligibility Criteria
Inclusion Criteria: * patients of high grade astrocytic glioma patients fit for surgery Exclusion Criteria: * patients of low grade glioma patients unfit for surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06214689 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying High Grade Astrocytoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06214689 currently recruiting?
Yes, NCT06214689 is actively recruiting participants. Contact the research team at adhamsalama001@gmail.com for enrollment information.
Where is the NCT06214689 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT06214689 clinical trial?
NCT06214689 is sponsored by Assiut University. The trial plans to enroll 35 participants.